Response: A Randomized, Open-Label, Phase Iii Study Of Ruxolitinib In Polycythemia Vera (Pv) Patients Resistant To Or Intolerant Of Hydroxyurea (Hu).

Srdan Verstovsek,Jean-Jacques Kiladjian,Victor Sandor, Jacek Lukawy,Jingjin Li,Shui He,William M. Garrett, Kamel Malek,Ulrich Pirron,Bijoyesh Mookerjee,Alessandro M. Vannucchi

JOURNAL OF CLINICAL ONCOLOGY（2012）

引用 0|浏览2

暂无评分

摘要

TPS203 Background: PV is a myeloproliferative neoplasm characterized by clonal stem cell proliferation causing increased red cell mass, blood hyperviscosity, significant morbidity, shortened lifesp...

查看译文

关键词

polycythemia vera,ruxolitinib,hydroxyurea,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要